Lumos Diagnostics (ASX:LDX) Reports 224% Rise in Product Revenue in Q1 FY27

Aditi Sarkar

27 October 2026 07:36 PM AEDT

Lumos Diagnostics (ASX:LDX) Reports 224% Rise in Product Revenue in Q1 FY27

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Product revenue rose 224% to US$0.56 million as US sites went live.
FebriDx live at 265 sites across 29 states, with 485 sites in evaluation.
Cash of US$11.8 million at 30 September 2026, with no debt.
New Carlsbad manufacturing facility scheduled to open by end of CY2026.

Lumos Diagnostics Holdings Limited (ASX:LDX) has released its Q1 FY27 results and commercial update for the quarter ended 30 September 2026. The update focuses on the US rollout of its FebriDx test following CLIA waiver, along with financial results and manufacturing progress. All figures are unaudited and in US dollars.

FebriDx Commercial Rollout

As at 11 October 2026, FebriDx was live at 265 sites across 29 states, an increase of 50 sites and three states since 15 September. A further 485 sites were in evaluation, up 20% over the same period.

Thirteen of the top 100 US urgent care groups are now engaged, with five live and eight evaluating. CEO Doug Ward said the commercial momentum since securing CLIA waiver for FebriDx continues to exceed expectations.

Quarterly Financial Results

Product revenue increased 224% to US$0.56 million, from US$0.17 million, as US sites went live. Total revenue fell 39% to US$2.04 million, mainly due to lower Hologic IP amortisation, while services revenue declined 32% to US$1.48 million.

Net operating cash outflow was US$4.7 million. Lumos ended the quarter with US$11.8 million in cash and no debt, after a US$1.0 million inventory build ahead of the flu season.

Paediatric Study and Manufacturing

The BARDA-funded paediatric study for children aged 2 to 12 has enrolled about 400 patients, and Lumos has received US$2.6 million of up to US$6.2 million in funding. Enrolment and bacterial-positive cases are below plan, and the company will discuss the study with the FDA by the end of CY2026.

A new ISO 13485-certified manufacturing facility in Carlsbad, California is scheduled to open by the end of CY2026, with capacity for up to 10 million tests a year once validated. The company's AGM is scheduled for 13 November 2026.

Key Takeaways

FebriDx adoption in the US is growing, with live sites and evaluations both increasing.
Product revenue rose sharply, while total revenue declined due to lower IP amortisation.
Lumos remains debt-free with US$11.8 million in cash.
Paediatric study enrolment is below plan, with FDA discussions due by end of CY2026.

FAQs

Q: What is FebriDx?

A: FebriDx is Lumos Diagnostics' test being rolled out across US urgent care sites following CLIA waiver.

Q: How many sites are using FebriDx?

A: FebriDx was live at 265 sites across 29 states as at 11 October 2026.

Q: How did product revenue perform in Q1 FY27?

A: Product revenue rose 224% to US$0.56 million.

Q: What was Lumos' cash position?

A: Lumos held US$11.8 million in cash at 30 September 2026, with no debt.

Q: When is the Lumos AGM?

A: The AGM is scheduled for 13 November 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.